Cargando…

Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma

BACKGROUND: The incorporation of genetic variables into risk scores for predicting venous thromboembolic events (VTE) could improve their capacity to identify those patients for whom thromboprophylaxis would be most beneficial. Proof‐of‐concept of this is provided by the TiC‐ONCO score for predictin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bastos‐Oreiro, Mariana, Ortiz, Javier, Pradillo, Virginia, Salas, Eduardo, Marínez‐Laperche, Carolina, Muñoz, Andrés, Buño, Ismael, Diéz‐Martin, José Luis, Soria, Jose Manuel, Pascual Izquierdo, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559493/ https://www.ncbi.nlm.nih.gov/pubmed/34598309 http://dx.doi.org/10.1002/cam4.4280

Ejemplares similares

Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin’s lymphoma
por: Bastos-Oreiro, Mariana, et al.
Publicado: (2021)

Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms
por: Carbonell, Diego, et al.
Publicado: (2019)

PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT
por: Ortuzar Pasalodos, A., et al.
Publicado: (2022)

Next Generation Cytogenetics in Myeloid Hematological Neoplasms: Detection of CNVs and Translocations
por: Chicano, María, et al.
Publicado: (2021)

EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment
por: Martínez-Laperche, C., et al.
Publicado: (2022)

Correction: EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment
por: Martínez-Laperche, C., et al.
Publicado: (2022)

Novel Candidate loci and Pathogenic Germline Variants Involved in Familial Hematological Malignancies Revealed by Whole-Exome Sequencing
por: Andrés-Zayas, Cristina, et al.
Publicado: (2023)

P1423: CIRCULATING CELL-FREE DNA KINETICS MEASURED BY DIGITAL PCR IN LYMPHOMA PATIENTS UNDERGOING CD19-CAR-T THERAPY
por: López-Esteban, M., et al.
Publicado: (2022)

Clinical utility of targeted next‐generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition
por: Andrés‐Zayas, Cristina, et al.
Publicado: (2021)

Methotrexate-Induced Subacute Neurotoxicity Surrounding an Ommaya Reservoir in a Patient with Lymphoma
por: Oarbeascoa, Gillen, et al.
Publicado: (2019)

ST2 and REG3α as Predictive Biomarkers After Haploidentical Stem Cell Transplantation Using Post-transplantation High-Dose Cyclophosphamide
por: Solán, Laura, et al.
Publicado: (2019)

Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer
por: Muñoz Martín, Andrés J., et al.
Publicado: (2018)

Venous thromboembolism and subsequent risk of cancer in patients with liver disease: a population-based cohort study
por: Montomoli, Jonathan, et al.
Publicado: (2015)

Novel biallelic variant in BBS9 causative of Bardet–Biedl syndrome: expanding the spectrum of disease-causing genetic alterations
por: Suárez-González, Julia, et al.
Publicado: (2021)

P1427: MONITORING CAR-T CELL IN B-CELL LYMPHOMA PATIENTS THROUGH SINGLE CHAIN VARIABLE FRAGMENT BY DIGITAL PCR
por: De La Iglesia San Sebastián, I., et al.
Publicado: (2022)

Elafin as a Predictive Biomarker of Acute Skin Graft-Versus-Host Disease After Haploidentical Stem Cell Transplantation Using Post-Transplant High-Dose Cyclophosphamide
por: Solán, Laura, et al.
Publicado: (2021)

Short Tandem Repeats (STRs) as Biomarkers for the Quantitative Follow-Up of Chimerism after Stem Cell Transplantation: Methodological Considerations and Clinical Application
por: Navarro-Bailón, Almudena, et al.
Publicado: (2020)

Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel
por: Martín‐Rojas, Reyes Maria, et al.
Publicado: (2022)

Pharmacological cancer treatment and venous thromboembolism risk
por: Muñoz Martín, Andrés J, et al.
Publicado: (2020)

Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide
por: Muñiz, Paula, et al.
Publicado: (2021)

Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation
por: Muñiz, Paula, et al.
Publicado: (2022)

Expression of Tissue Factor in Epithelial Ovarian Carcinoma Is Involved in the Development of Venous Thromboembolism
por: Sakurai, Manabu, et al.
Publicado: (2017)

Management of venous thromboembolism in patients with lung cancer: a state-of-the-art review
por: Xiong, Wei, et al.
Publicado: (2023)

Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy
por: Rodríguez-Macías, Gabriela, et al.
Publicado: (2023)

A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts
por: Muñoz, Andrés, et al.
Publicado: (2023)

Multilocus Genetic Risk Scores for Venous Thromboembolism Risk Assessment
por: Soria, José Manuel, et al.
Publicado: (2014)

Keeping RelApse in Chk: molecular mechanisms of Chk1 inhibitor resistance in lymphoma
por: Black, Elizabeth M., et al.
Publicado: (2022)

Safety and Effectiveness of Direct Oral Anticoagulants for the Treatment of Gastrointestinal Cancer-Associated Venous Thromboembolism
por: Ullah, Fauzia, et al.
Publicado: (2023)

Antibacterial Activity of Polymer Nanocomposites Incorporating Graphene and Its Derivatives: A State of Art
por: Díez-Pascual, Ana M., et al.
Publicado: (2021)

Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients
por: Hu, Maogui, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain
por: Bastos-Oreiro, Mariana, et al.
Publicado: (2022)

R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group
por: Sancho, Juan‐Manuel, et al.
Publicado: (2021)

Application of Machine Learning to the Prediction of Cancer-Associated Venous Thromboembolism
por: Mantha, Simon, et al.
Publicado: (2023)

FLT3-ITD Expression as a Potential Biomarker for the Assessment of Treatment Response in Patients with Acute Myeloid Leukemia
por: Carbonell, Diego, et al.
Publicado: (2022)

Incidence, risk factors, and outcomes of central venous catheter‐related thromboembolism in breast cancer patients: the CAVECCAS study
por: Debourdeau, Philippe, et al.
Publicado: (2017)

Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real‐world evaluation
por: Baker, Hailey A., et al.
Publicado: (2018)

Exome sequencing reveals heterogeneous clonal dynamics in donor cell myeloid neoplasms after stem cell transplantation
por: Suárez-González, Julia, et al.
Publicado: (2020)

Angiotensin II enhances the proliferation of Natural Killer/T-cell lymphoma cells via activating PI3K/Akt signaling pathway
por: Zhang, Gui-Hua, et al.
Publicado: (2020)

Predictive Ability of a Clinical-Genetic Risk Score for Venous Thromboembolism in Northern and Southern European Populations
por: Salas, Eduardo, et al.
Publicado: (2021)

A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center
por: Vu, Khanh, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2ioejdnd8lf95miqi414aoh63k